Nafoxidine

• UNSPSC Description:

  Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.

• Target Antigen:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nafoxidine.html

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  COC1=CC(CCC(C2=CC=CC=C2)=C3C4=CC=C(OCCN5CCCC5)C=C4)=C3C=C1

• Molecular Weight:

  425.56

• References & Citations:

  [1]Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10(8):905-912. |[2]De Lorenzo MS, Farina HG, Alonso DF, Gomez DE. Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 2004;24(3a):1737-1743.|[3]Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol. 2004;27(4):384-388.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1845-11-0